mRNA expression and promoter DNA methylation status of CDKi p21 and p57 genes inex vivoexpanded CD34+cells following co-culture with mesenchymal stromal cells and growth factors

Hematology ◽  
2013 ◽  
Vol 18 (1) ◽  
pp. 30-38 ◽  
Author(s):  
Mohammad Soleiman Soltanpour ◽  
Naser Amirizadeh ◽  
Farhad Zaker ◽  
Arezoo Oodi ◽  
Mahin Nikougoftar ◽  
...  
2015 ◽  
Vol 167 (2) ◽  
pp. 147-154 ◽  
Author(s):  
Marta Zajacova ◽  
Anna Kotrbova-Kozak ◽  
Pavel Cepek ◽  
Marie Cerna

2010 ◽  
Vol 2 (1) ◽  
pp. 181-187 ◽  
Author(s):  
YOUNGIL KOH ◽  
DAE-YOUNG KIM ◽  
SUNG-HYO PARK ◽  
HYANG-MIN BYUN ◽  
INHO KIM ◽  
...  

Author(s):  
Francisco Álvarez-Nava ◽  
Marco Salinas ◽  
Daniela Bastidas ◽  
Yosselin Vicuña ◽  
Marcia Racines-Orbe

AbstractObjectivesReduced gene expression of PPARGC1A in subjects with insulin resistance (IR) has been reported. Insulin resistance occurs early on the course of Turner syndrome (TS). The main objective of this study was to evaluate the relationship between PPARGC1A promoter DNA methylation status in lymphocytes and insulin sensitivity and secretion in Ecuadorian females with TS.MethodsWe examined a cohort of 34 Ecuadorian patients with TS along with a sex-, age- and BMI-matched reference group. All subjects received a standard 75 g oral glucose tolerance test. Insulin resistance and secretion indices were calculated. The PPARGC1A methylated DNA/unmethylated DNA ratio and mitochondrial content (mtDNA/nDNA ratio) were further determined.ResultsNotably, the PPARGC1A DNA methylation level was significantly higher in TS subjects than the reference group and correlated with IR indices. Conversely, mitochondrial content was significantly lower in the study group than healthy controls and negatively correlated with the PPARGC1A methylated DNA/unmethylated DNA ratio in TS individuals. PPARGC1A promoter DNA methylation status contributed to 20% of the total variability in Homeostasis Model Assessment for Insulin Resistance (HOMA-IR) independently of BMI or age in TS subjects.ConclusionsOur collective findings suggest that expression of PPARGC1A and lower mitochondrial number affect the metabolic phenotype in TS subjects.


PLoS ONE ◽  
2021 ◽  
Vol 16 (12) ◽  
pp. e0260303
Author(s):  
Hiroki Harada ◽  
Yusuke Nie ◽  
Ippeita Araki ◽  
Takafumi Soeno ◽  
Motohiro Chuman ◽  
...  

Promoter DNA methylation of MutL homolog 1 (MLH1) is considered to play a causative role in microsatellite instability (MSI) carcinogenesis in primary gastric cancer, and a high MSI status is associated with treatment sensitivity to human cancers. Nevertheless, clinicopathological analysis is defective for MLH1 methylation status in a quantitative manner. We newly developed quantitative methylation specific PCR using a TaqMan probe and applied it to 138 patients with primary gastric cancer who underwent gastrectomy in addition to basic molecular features such as MSI, Epstein Barr virus, and other DNA methylation status. (1) In primary gastric cancer, median methylation value was 0.055, ranging from 0 to 124.3. First, MLH1 hypermethylation was strongly correlated with MSI-High/MSI-Low status and suppressed immunostaining (P < 0.0001). (2) The MLH1 hypermethylation was associated with advanced age (P = 0.0048), antral location (P = 0.0486), synchronous multiple gastric cancer (P = 0.0001), and differentiated histology (P = 0.028). (3) Log-rank plot analysis identified the most relevant cut-off value (0.23) to reflect gentle phenotypes in MLH1 hypermethylation cases (P = 0.0019), especially in advanced gastric cancer (P = 0.0132), which are designated as haploinsufficiency of MSI (MSI-haplo) phenotype in this study. (4) In synchronous multiple gastric cancer, MLH1 hypermethylation was not necessarily confirmed as field cancerization. (5) MSI-haplo defined by MLH1 methylation status represented distinct prognostic phenotype even after molecular classifications. MLH1 hypermethylation designated as MSI-haplo may represent unique prognostic phenotype during gastric carcinogenesis.


2014 ◽  
Vol 32 (4_suppl) ◽  
pp. 452-452
Author(s):  
Jens Bedke ◽  
Pascale Fisel ◽  
Stefan Winter ◽  
Stephan Kruck ◽  
Marcus Scharpf ◽  
...  

452 Background: The monocarboxylate transporter 4 (MCT4) is a metabolic target in tumor biology because it mediates lactate transport across membranes resulting in antiapoptotic effects. Cell experiments support the importance of MCT4 in clear cell renal cell carcinoma (ccRCC). In this study, we assessed the prognostic potential of MCT4 expression in ccRCC and its epigenetic regulation by DNA methylation as novel predictive marker for patient outcome using independent ccRCC cohorts. Methods: MCT4 protein expression was quantified in 207 ccRCC and corresponding nontumor tissues. Data of an independent ccRCC cohort from The Cancer Genome Atlas (TCGA) were analyzed on MCT4 mRNA (n = 482) and DNA methylation (n = 283) level. The findings on MCT4 expression and DNA methylation in the SLC16A3 promoter were validated in a third cohort (n = 64). Promoter activity assays were conducted in four RCC cell lines. Results: MCT4 protein expression was upregulated (p < 0.0001) in ccRCC and showed significant association with cancer-related death. Upregulation of MCT4 mRNA expression (p < 0.00001) was confirmed in the TCGA cohort. Single CpG sites correlated inversely with mRNA expression and were associated with overall survival in Kaplan-Meier analyses [HR = 0.39; 95% confidence interval (CI), 0.24-0.64; P[log-rank] = 1.23e(-04)]. Promoter activity studies confirmed MCT4 regulation by DNA methylation. The significant correlation between MCT4 protein and gene expression or DNA methylation at single CpG sites was validated in a third cohort. Again, higher methylation at individual CpG sites was associated with prolonged survival [HR = 0.05; 95% CI, 0.01-0.40; P[log-rank] = 6.91e(-05)]. Conclusions: This study identified SLC16A3 promoter DNA methylation as a novel epigenetic mechanism for MCT4 regulation in ccRCC. First evidence of a biological rationale for prognosis and clinical outcome is supported by this specific SLC16A3 promoter DNA methylation.


Neuroscience ◽  
2012 ◽  
Vol 220 ◽  
pp. 41-46 ◽  
Author(s):  
T.K. Furuya ◽  
P.N.O. Silva ◽  
S.L.M. Payão ◽  
P.H.F. Bertolucci ◽  
L.T. Rasmussen ◽  
...  

Author(s):  
Veronika L. Pistek ◽  
Rainer W. Fürst ◽  
Heike Kliem ◽  
Stefan Bauersachs ◽  
Heinrich H.D. Meyer ◽  
...  

2013 ◽  
Vol 25 (1) ◽  
pp. 191 ◽  
Author(s):  
V. L. Pistek ◽  
R. W. Fürst ◽  
S. Bauersachs ◽  
H. S. Kliem ◽  
H. H. D. Meyer ◽  
...  

In utero and early postnatal exposure to exogenous oestrogens may alter the epigenome, possibly influencing health later in life. The reproductive organs are the main target of oestrogens. Uterine HOXA10 expression and promoter DNA methylation have been shown to be sensitive to endocrine disruptors in rodents. In the endometrium of pigs, in vitro exposure to estradiol-17β resulted in an increase of HOXA10 mRNA and protein expression, and a regulation for HOXA10 has also been shown during early pregnancy. However, it is unclear whether modification in promoter DNA methylation was involved herein. In the present study, we investigated the effect of oral estradiol-17β supplementation to pregnant pigs from Day 0 until delivery (0, 0.05, 10, and 1000 µg kg–1 per day; n = 8–12/group) on HOXA10 expression and promoter DNA methylation in the uterus of prepubertal and the endometrium of postpubertal porcine offspring. In addition, endometrial samples from 2 physiological situations were analyzed, namely the oestrous cycle at Day 0, 3, 6, 12, and 18 (n = 6/day), and early pregnancy at Day 10, 12, and 14 (n = 4/day). Furthermore, different reproductive and nonreproductive tissues from pre- and postpubertal untreated animals were investigated (n = 2/tissue). Gene expression was measured using RT-qPCR. The DNA was first bisulfite converted, amplified by using methylation-sensitive high-resolution melting qPCR, followed by pyrosequencing. Statistical analyses were conducted using one-way ANOVA. In utero estradiol-17β exposure did neither alter HOXA10 expression compared to the control group nor HOXA10 promoter DNA methylation in pre- and postpubertal porcine offspring, respectively. Because the prepubertal group displayed higher HOXA10 mRNA expression than did postpubertal animals, while DNA methylation was lower in the younger animals, a potential role of DNA methylation may be assumed. During the oestrous cycle, HOXA10 expression was significantly regulated (P < 0.001); it was highest at oestrous (Day 0), decreased 2.5-fold by Day 3, and increased again 1.5-fold by Day 6. In early pregnant sows, endometrial HOXA10 transcripts were significantly higher at Day 14 (P = 0.031) compared with nonpregnant controls. In both settings promoter DNA methylation did not change. Regarding HOXA10 expression between different tissues, the DNA methylation at one CpG site was significantly correlated with mRNA expression in prepubertal animals (R2 = 0.582) but not in the adult (R2 = 0.004). We conclude that HOXA10 expression is regulated through other mechanisms than is promoter DNA methylation in adult sows. Still, in prepubertal pigs promoter DNA methylation may influence HOXA10 expression. In utero estradiol-17β exposure did not affect HOXA10 expression and promoter DNA methylation.


2019 ◽  
Vol 697 ◽  
pp. 134156 ◽  
Author(s):  
Chenyang Ji ◽  
Siqing Yue ◽  
Jinping Gu ◽  
Yuan Kong ◽  
Haofeng Chen ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document